Cholecystokinin (CCK) is a neuropeptide that affects growth rate in chickens by regulating appetite. CCK peptides exert their function by binding to two identified receptors, CCKAR and CCKBR in the GI tract and the brain, respectively, as well as in other organs. In mammals, CCK/CCKAR interactions affect a number of immunological parameters, including regulation of lymphocytes and functioning of monocytes.

CCK, also known as pancreozymin, is synthesized and secreted by enteroendocrine cells in the duodenum. The main function of CCK is to cause the release of digestive enzymes and bile from the pancreas and gallbladder, respectively. It also induces drug tolerance to opioids like morphine and heroin. Cholecystokinin (CCK) has strong bioactivity in the regulation of a number of cell activities.
# Cholecystokinin Receptor Antagonists, Agonists & Inhibitors

## CCK-A receptor inhibitor 1

Cat. No.: HY-U00387

CCK-A receptor inhibitor 1 is a **cholecystokinin A (CCK-A)** receptor inhibitor with a binding IC$_{50}$ of 340 nM.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

## CCK-B Receptor Antagonist 1

Cat. No.: HY-U00360

CCK-B Receptor Antagonist 1 is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

**Purity:** 99.04%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

---

## Ceruletide

(Caerulein; Cerulein; FI-6934)

Cat. No.: HY-A0190

Ceruletide, a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea, is a potent cholecystokininetic agent, and acts as a **cholecystokinin receptor agonist**.

**Purity:** 99.96%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

## CHEMBL333994

(FK-480)

Cat. No.: HY-U00363

CHEMBL333994 is a potent and orally effective Cholecystokinin A (CCK-A) antagonist, with an IC$_{50}$ of 0.67 nM.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg, 20 mg

---

## Gastrin-CCK antagonist 1

Cat. No.: HY-U00375

Gastrin-CCK antagonist 1 is an antagonist of gastrin/CCK, used for the research of gastrointestinal disorders.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

## Gastrin-1, human

Cat. No.: HY-P1097

Gastrin-1, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

**Purity:** 98.41%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

---

## Dexloxiglumide

Cat. No.: HY-128878

Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8).

**Purity:** 98.25%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

---

## Gl 181771

Cat. No.: HY-11076

Gl 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 250 mg, 500 mg

---

## Lorglumide sodium salt

(CR-1409 (sodium salt))

Cat. No.: HY-B1439B

Lorglumide sodium salt (CR-1409 sodium salt) is a potent **cholecystokinin (CCK) receptor antagonist**.

**Purity:** >99.0%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg

---

## Loxiglumide

(CR-1505)

Cat. No.: HY-B2154

Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist.

**Purity:** >98.0%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

---

Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@MedChemExpress.com
### Mini Gastrin I, human

Cat. No.: HY-P1593

Mini Gastrin I, human is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

### Mini Gastrin I, human TFA

Cat. No.: HY-P1593A

Mini Gastrin I, human (TFA) is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

### Nastorazepide (Z-360)

Cat. No.: HY-17617

Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity.

**Purity:** 99.89%

**Clinical Data:** Phase 2

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Proglumide

Cat. No.: HY-B1330

Proglumide is a known cholecystokinin (CCK) antagonist.

**Purity:** 99.74%

**Clinical Data:** Launched

**Size:** 10 mM × 1 mL, 100 mg

### Sograzepide (Netazepide; YF 476; YM-220)

Cat. No.: HY-14850

Sograzepide (Netazepide;YF476) is a gastrin/cholecystokinin 2 receptor (CCK2) antagonist.

**Purity:** 98.04%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### SR 146131

Cat. No.: HY-11077

SR 146131 is a potent, orally available, and selective nonpeptide (cholecystokinin 1) receptor agonist.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 250 mg, 500 mg

### Tarazepide

Cat. No.: HY-U00062

Tarazepide is a potent and specific CCK-A receptor antagonist.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg, 20 mg